Background: Babies with congenital hydrocephalus often experience developmental disabilities due to brain injury associated with prolonged increased pressure on the developing brain parenchyma. Umbilical cord blood (CB) infusion has favorable effects in animal models of brain hypoxia and stroke and is being investigated in clinical trials of brain injury in both children and adults. We sought to establish the safety and feasibility of repeated intravenous infusions of autologous CB in young babies with congenital hydrocephalus. Methods: Infants with severe congenital hydrocephalus and an available qualified autologous CB unit traveled to Duke for evaluation and CB infusion. When possible, the CB unit was utilized for multiple infusions. Patient and CB data were obtained at the time of infusion and analyzed retrospectively. results: From October 2006 to August 2014, 76 patients with congenital hydrocephalus received 143 autologous CB infusions. Most babies received repeated doses, for a total of two (n = 45), three (n = 18), or four (n = 4) infusions. There were no infusion-related adverse events. As expected, all babies experienced developmental delays. conclusion: Cryopreserved CB products may be effectively manipulated to provide multiple CB doses. Repeated intravenous infusion of autologous CB is safe and feasible in young babies with congenital hydrocephalus.h ydrocephalus results from an excessive accumulation of cerebral spinal fluid (CSF) within the ventricular system of the brain resulting in a progressive increase in ventricular volume and intracranial pressure. It may be caused by a blockage within the ventricular system, overproduction of cerebral spinal fluid, or decreased absorption of cerebral spinal fluid.The incidence of congenital hydrocephalus has been estimated as 0.3 to 1.5 per 1,000 live births (1,2). Congenital hydrocephalus may occur in isolation or as a result of neural dysgenesis, such as spina bifida or a Dandy Walker malformation. Though many patients with congenital hydrocephalus are suspected to have a genetic cause, a causal mutation is identified in only a small portion of patients, most commonly X-linked hydrocephalus due to a mutation in L1CAM (3). Various other chromosomal abnormalities have been described in babies with hydrocephalus with additional associated somatic defects. Such genetic cases can usually be identified before or at birth.Most cases of congenital hydrocephalus are diagnosed in utero on routine prenatal, screening ultrasonography when macrocephaly and/or ventriculomegaly are seen. Typically signs of hydrocephalus are first recognized between 15-10 wk of gestation. Options at the time of an in utero diagnosis of severe hydrocephalus are currently limited to termination of the pregnancy or expectant management. Fetal shunt placement has been attempted, but technical issues with the shunt and mixed patient outcomes resulted in a moratorium on fetal percutaneous shunting in the United States since 1985 (4,5).Current standard management of a baby with severe congeni...